Completed Trials

EPO-TBI

EPO-TBI

EPO-TBI was an international, double-blind, randomised controlled trial investigating erythropoietin (EPO) treatment in over 600 patients with traumatic brain injury. The group has concluded that erythropoietin does not improve functional outcome at six months as would be shown by a reduction in the number of patients with an Extended Glasgow Outcome Scale (GOS-E) measure of 4 or lower. While there are some indications that EPO treatment might reduce mortality in patients with traumatic brain injury, rigorous future investigations are required in this patient population before its routine use could be recommended.

Read more


HARP II

HARP II

In this multicenter, double-blind clinical trial, patients with an onset of ARDS within the previous 48 hours were randomly assigned (in a 1:1 ratio) to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days.

Read more


ARISE

ARISE

The ARISE RCT was a multi-centre, randomised controlled trial of the effect of early goal-directed therapy, compared to standard care, on 90-day mortality in patients presenting to the Emergency Department with severe sepsis.

Patients were randomised in the ED to receive either EGDT for a total of 6 hours post-randomisation, or standard care. Patients assigned to receive EGDT were cared for by the dedicated ARISE study team. The patient received treatment as per the study protocol for 6 hours with central blood oxygen levels as the target end-point, and then received standard care. Patients assigned to receive standard care continued to be cared for by the hospital team in accordance with current best practice. Patients in both groups received any additional treatment needed, such as antibiotics or surgery.

The study was conducted in multiple sites with 1600 patients enrolled in the study over a 2.5 year period

Read more


POINT PREVALANCE

POINT PREVALANCE

This program acts as an observational study, without any intervention, and involves collecting data on topics of interest, in patients in multiple intensive care units, on a specific day or days. It provides no information on outcomes, but provides very important information on how common a problem is, and what is currently being done to manage that problem. This is an ongoing program consisting of multiple research collection days, each performing multiple, independent studies simultaneously, including a number of paediatric studies.